Concept

Safety Profile

ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib

"Treatment-emergent adverse events (TEAEs) were consistent with prior reports and included any-grade EGFR inhibition-related paronychia (78%), rash (65%), diarrhea and stomatitis (each 35%), and pruritus (31%); and MET inhibition-related hypoalbuminemia (61%) and peripheral edema (41%).\n\nTEAEs of grade 3 or higher included EGFR inhibition-related paronychia (8%) and rash (14%), and MET inhibition-related hypoalbuminemia (6%) and peripheral edema (2%). Other TEAEs of grade 3 or higher included infusion-related reactions in 6% of patients, ALT elevation in 4%, AST elevation in 2%, and nausea in 2%. Twenty patients (41%) developed COVID-19 during the trial, 1 of whom had symptoms of grade 3 or higher."

Related Ideas

  • Survival OutcomesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
  • Safety ProfileASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CROWN: 7-Year Update for Lorlatinib
  • Safety SignalsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
  • Safety OutlookASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
  • Monitoring Update10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 3. A Shorter Hospital Stay for Imdelltra
  • Testing Effects10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 9. Lyrfigtu for FGFR2-Positive Bile Duct Cancer
Safety Profile | ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor | Bifalgorithm | Bifalgorithm